Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Management Fights Back Following Biosimilar Rejection

CEO And COO Buy Up nearly 140,000 Shares To ‘Reinforce Trust’

Executive Summary

Prestige BioPharma’s top brass are looking to restore shareholder confidence following the surprise failure of their trastuzumab biosimilar before the EMA’s CHMP.

You may also be interested in...



Prestige Pulls Trastuzumab After EMA Knockback

Prestige Biopharma has formally withdrawn its marketing authorization application for its Tuznue (trastuzumab) biosimilar candidate, following a negative opinion from the EMA’s CHMP as well as a requested re-examination.

Prestige Brings In New Management As It Consolidates CDMO Control

Prestige Biopharma says it is acting to “consolidate group competitiveness” by taking an increased share in Prestige Biologics, at the same time as a new CEO was appointed for the CDMO.

EMA Re-Examines Decisions On Prestige’s Trastuzumab And Synchron Studies

Following decisions by the EMA’s CHMP to deny Prestige Biopharma a marketing authorization for its trastuzumab biosimilar and to suspend the marketing authorizations of dozens of generics due to concerns over bioequivalence tests, the European regulator has confirmed it will review the opinions.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel